Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
MindBio Therapeutics Corp
C.MBIO
Healthcare
Biotechnology
MindBio Therapeutics Corp. is a biotech/biopharma company. It creates novel and emerging treatments for mental health conditions and is conducting take-home Microdosing (MB22001) human clinical trials. MB22001 is its lead candidate drug, a titratable form of Lysergic Acid Diethylamide designed for take-home microdosing. It is focused on microdosing of psychedelic medicines and is advancing its...
drug and technology protocols through clinical trials. It develops a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed Phase 1 clinical trials in 80 healthy participants and has completed a Phase 2a clinical trial in patients with Major Depressive Disorder. The underway are two Phase 2B trials, one in cancer patients experiencing existential distress and another in patients with Major Depressive Disorder. It invests in research that forms the basis for developing novel and clinically proven treatments.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (CSE:MBIO)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
Next
(28)
•••
diamondlessnono
X
View Profile
View Bullboard History
Comment by
diamondlessnono
on Apr 22, 2024 3:03pm
RE:RE:Good News
Can't find no inside buying?
(189)
•••
Kensin1953
X
View Profile
View Bullboard History
Comment by
Kensin1953
on Apr 18, 2024 11:59am
RE:Good News
Agreed. Weeks away from positive results. Smart move . JMHO
GameSquare Holdings Reports Record 2024 Third Quarter Results
posted Nov 15, 2024 9:00am by
GameSquare Holdings Inc.
-
|
Justin Kenna, CEO of GameSquare, stated, "GameSquare delivered strong third quarter financial results that were in line with our pre-announcement, and reflect the strategies underway to drive organic sales growth, complete the integration of our recent acquisitions, and build a profitable organization. On a sequential basis, I am encouraged by the ...read more
(744)
•••
Smokey1958
X
View Profile
View Bullboard History
Post by
Smokey1958
on Apr 16, 2024 5:11pm
Good News
Riverfort Global Opportunities has been working with MBIO since before their move to become public. This move to,convert the loan to shares does not appear to be some desperate attempt by RGO to
...more
(744)
•••
Smokey1958
X
View Profile
View Bullboard History
Post by
Smokey1958
on Apr 12, 2024 11:24am
Filing With CSE
https://webfiles.thecse.com/CSE_Form_7_-_Monthly_Progress_Report_MBIO_-_March_2024.docx?LuBvZRwOGlXZ7Isorb4Rnt_vIcBKtIRH
(8)
•••
Loony
X
View Profile
View Bullboard History
Post by
Loony
on Apr 06, 2024 12:23am
Justin Case LSD!
https://finance.yahoo.com/quote/MBIO.CN/community
(8)
•••
Loony
X
View Profile
View Bullboard History
Post by
Loony
on Mar 20, 2024 8:16am
Mindbio News.
https://www.tipranks.com/news/company-announcements/mindbio-launches-pioneering-depression-microdosing-trial
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Mar 20, 2024 4:51am
New Press Release - MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder
First doses of MB22001 administered in Phase 2B take-home trial in patients with Major Depressive Disorder.Follows successful Phase 2A trial where 53% of depressed patients were in complete remission from their depression at week 8 marked by a mean 14.1 point drop in MADRS score (Montgomery...
read article.
(744)
•••
Smokey1958
X
View Profile
View Bullboard History
Post by
Smokey1958
on Mar 08, 2024 8:31am
Europe and Mental Health
This is a fantastic article on the current state of trials for alternative drug therapies for mental health conditions across Europe. Immediately two things come to the fore including the following:
...more
(744)
•••
Smokey1958
X
View Profile
View Bullboard History
Post by
Smokey1958
on Mar 07, 2024 7:13pm
MindMed NR
Most here have probably heard the news for MindMed. If you haven't, this news could (should) be fantastic for MBio as well. Being on the radar of the FDA in the US means cash infusions and a much
...more
(744)
•••
Smokey1958
X
View Profile
View Bullboard History
Post by
Smokey1958
on Mar 04, 2024 8:36pm
First Paper Published Last Year
https://researchspace.auckland.ac.nz/handle/2292/66460
(744)
•••
Smokey1958
X
View Profile
View Bullboard History
Post by
Smokey1958
on Mar 04, 2024 8:32pm
Those Interested Here and on CEO
Dr. Suresh Muthukumaraswamy, the person doing a great deal of the heavy lifting for MBio. https://profiles.auckland.ac.nz/sd-muthu/publications Some of the papers connected to these early days of LSD
...more
(744)
•••
Smokey1958
X
View Profile
View Bullboard History
Post by
Smokey1958
on Mar 04, 2024 7:02am
New Press Release
and so it continues! With an increasing number of participants this double blind trial introducing a placebo will have a significant influence on any questions associated with placebo effect. Should
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Mar 04, 2024 5:02am
New Press Release - MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder
Ethics and regulatory approvals finalized for world-first take-home use of a psychedelic medicine MB22001 in placebo-controlled trial in depressed patients n=90Recruitment of clinical trial participants underwayFollows successful Phase 2a trial where 53% of depressed patients in complete...
read article.
(744)
•••
Smokey1958
X
View Profile
View Bullboard History
Post by
Smokey1958
on Feb 28, 2024 9:11am
Ahead of the Game
If the following document is any indication MBio appears to be ahead of the game. As this document on FDA expectations for drug trials, released in June 2023, is in draft only it is unlikely trials
...more
(744)
•••
Smokey1958
X
View Profile
View Bullboard History
Post by
Smokey1958
on Feb 27, 2024 10:51am
Apples to Oranges
For whatever reason there seems to be a significantly higher number of ongoing studies with psilocybin as compared to MBio which seems almost lone wolf in trials using LSD. As is now being discussed
...more
Prev
1
2
3
4
5
6
7
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
New Gold and Copper Hotspot Identified – What’s Next for This Serbian Project?
Explained: The Psychology of Options Trading with Practical Tips
Geodrill Generates Revenue of $34.1M, a 13% Increase Compared to $30.3M for Q3-2023
Major Funding Secured! Company Closes First Round of Private Placement
This $10M Deal Could Reshape the Future of Global Creator Platforms
Have you held units of a TD mutual fund (other than through a discount broker)? Learn more.
Gold, growth and sustainability in focus for this resource company
Coppernico Drills 19 Meters of 0.50% Copper in First 5 Holes and Applies for Additional Permits